Global sales expansion of cardiovascular products such as Ultimaster

「Overseas revenue increased 21.2% year on year as all businesses grew, led by the Interventional Systems business.」

「Overseas, all businesses grew, led by the Interventional Systems business, resulting in an 8.6% year-on-year increase in revenue. In Japan, sales in the Interventional Systems and neuro businesses remained strong, resulting in a 5.9% year-on-year increase in revenue.」

「Despite the downward impact of foreign exchange movements, overseas revenue increased 4.9% year on year, led by the Interventional Systems business. In Japan, sales in the Interventional Systems and neuro businesses increased, resulting in a 7.7% year-on-year increase in revenue. As a result, global revenue increased 5.2% year on year to ¥322.1 billion.」

「In the Interventional Systems business, the company obtained MDR approval to expand the indications for the drug-eluting coronary stents Ultimaster Nagomi and Ultimaster Tansei.」

「Overseas, all businesses grew, led by the TIS and neurovascular businesses, resulting in a 16.9% year-on-year increase in revenue. In Japan, sales in the vascular and neurovascular businesses remained strong, but revenue from the TIS business declined, resulting in a marginal 0.2% year-on-year increase. As a result, global revenue increased 15.3% year on year to ¥306.3 billion.」

「At the Cardiovascular Company, the drug-eluting coronary stent Ultimaster Nagomi received CE marking certification demonstrating compliance with the European Union (EU) safety requirements, and sales began in the European market. The company also began a post-market clinical follow-up study of Ultimaster Nagomi in Europe. The study is being conducted in cooperation with 60 medical institutions in the EU and is expected to enroll 3,000 patients.」

「Overseas, revenue increased 14.7% year on year, led by the TIS (catheter) and neurovascular businesses. In Japan, the number of endovascular treatment procedures recovered, resulting in a 4.6% year-on-year increase in revenue. As a result, global revenue increased 13.6% year on year to ¥407.7 billion.」

「Overseas, demand expanded in the TIS (catheter) and vascular businesses, resulting in a 13.9% year-on-year increase in revenue. In Japan, the number of endovascular treatment procedures recovered, resulting in a 4.3% year-on-year increase in revenue. As a result, global revenue increased 12.9% year on year to ¥265.7 billion.」

「Overseas, revenue increased 13.0% year on year, driven by expanding demand for the TIS (catheter) business as well as contributions from new products in the vascular business. As a result, global revenue increased 11.8% year on year to ¥130.6 billion.」

「In the TIS business, the company announced the results of two clinical trials in the United States. The trials evaluated lower-limb catheter treatment (R2P, Radial to Peripheral) and abdominal catheter treatment (R.A.V.I., Radial Access for Visceral Intervention), both performed using radial access through an artery in the wrist.」

「In Japan, the recovery in medical demand was delayed by the impact of the eighth wave of COVID-19, resulting in a slight year-on-year decline in revenue. Within this context, revenue in the vascular business increased significantly due to the impact of new products. Overseas, all businesses performed well as medical demand recovered and grew, led by the vascular business, which benefited from new products, and revenue increased 25.2% year on year. As a result, global revenue increased 21.9% year on year to ¥358.9 billion.」

「In Japan, the recovery in medical demand was delayed by the impact of the seventh wave of COVID-19, resulting in a slight year-on-year decline in revenue. Within this context, revenue in the vascular business increased significantly due to the impact of new products. Overseas, all businesses performed well as medical demand recovered and grew, led by the vascular business, which benefited from new products, and revenue increased 24.3% year on year. As a result, global revenue increased 21.1% year on year to ¥235.4 billion.」

「Overseas, demand in the TIS and neurovascular businesses showed a marked recovery in North America and Asia, and global revenue increased 17.3% year on year to ¥116.8 billion.」

「In the neurovascular business, the company launched the FRED X flow-diverting stent for the treatment of cerebral aneurysms in the United States.」

「In Japan, demand recovered in the TIS and neurovascular businesses, resulting in higher revenue. Overseas, demand in the TIS and neurovascular businesses showed a marked recovery in North America and Europe, and global revenue increased 23.5% year on year to ¥294.4 billion.」

「In Japan, demand recovered in the TIS and neurovascular businesses, resulting in higher revenue. Overseas, demand in the TIS and neurovascular businesses showed a marked recovery in North America and Europe, and global revenue increased 30.1% year on year to ¥194.3 billion.」

「In Japan, demand for the TIS and Neurovascular businesses recovered, resulting in higher revenue. Overseas, demand for the TIS and Neurovascular businesses recovered markedly in North America and Europe, and global revenue increased 47.9% year on year to ¥99.6 billion.」

「In Japan, the flow-diverter stent FRED was launched in April 2020, the carotid stent CASPER Rx in September, and the Woven EndoBridge device for treating cerebral aneurysms in December.」

「In Japan, auxiliary circulatory devices such as ECMO systems in the Cardiovascular business and flow-diverter stents in the Neurovascular business drove performance, but the impact of the spread of COVID-19 on other businesses was substantial, resulting in lower revenue. Overseas, the impact on the TIS (catheter) business was significant in the Americas, while in China the Neurovascular business was affected by the timing of orders from distributors. As a result, Cardiovascular Company revenue fell 9.5% year on year to ¥238.4 billion.」

「In Japan, auxiliary circulatory devices such as ECMO systems in the Cardiovascular business, flow-diverter stents and thrombus aspiration catheters in the Neurovascular business, and other products drove performance, but the impact of the spread of COVID-19 on other businesses was substantial, resulting in lower revenue. Overseas, the impact on the TIS (catheter) business was significant in the Americas, while in China the Neurovascular business was affected by the timing of orders from distributors. As a result, Cardiovascular Company revenue fell 13.4% year on year to ¥149.4 billion. Meanwhile, demand recovered markedly, particularly overseas, as some procedures postponed from the first quarter were performed in the second quarter.」

「In Japan, auxiliary circulatory devices such as ECMO systems in the Cardiovascular business drove performance, but the impact of the spread of COVID-19 on other businesses was substantial, resulting in lower revenue. Overseas, the impact was particularly significant on the TIS (catheter) business in the Americas and Europe, and Cardiovascular Company revenue fell 23.9% year on year to ¥67.3 billion.」

「A longer version of Misago, a stent for treating peripheral artery disease that reaches from the blood vessels in the wrist to lesions in the legs, was added to the lineup and launched in the United States in October 2019.」

「In Japan, the TIS (catheter) business, centered on imaging, and Neurovascular products for treating cerebral infarction drove performance. Overseas, WEB, the Neurovascular business's intrasaccular device for treating cerebral aneurysms, was a driver. In addition, the TIS (catheter) business performed well, resulting in a 9.3% year-on-year increase in Cardiovascular Company revenue to ¥263.5 billion.」

「In Japan, stent grafts for which direct sales began in the Vascular business, and overseas, WEB, the Neurovascular business's intrasaccular device for treating cerebral aneurysms, drove performance. In addition, the global TIS (catheter) business performed well, resulting in a 12.5% year-on-year increase in Cardiovascular Company revenue to ¥172.6 billion.」

「In Japan, stent grafts for which direct sales began in the Vascular business, and overseas, WEB, the Neurovascular business's intrasaccular device for treating cerebral aneurysms, drove performance. In addition, the global TIS (catheter) business performed well, resulting in a 11.3% year-on-year increase in Cardiovascular Company revenue to ¥88.5 billion.」

「The next-generation product of the existing drug-eluting coronary stent Ultimaster, Ultimaster Tansei, was launched in Europe in May 2018 and in Japan in September 2018.」

「Although the Neurovascular business performed well, revenue at the Cardiovascular Company fell 2.6% year on year to ¥153.5 billion due to the impact of Japan's official drug price revision and shipment delays from the Aitaka plant for some products.」

「Overseas, access and oncology products in the TIS business, as well as hydrogel-based coils for treating cerebral aneurysms and aspiration catheters in the Neurovascular business, drove performance. As a result, revenue at the Cardiovascular Company increased 0.6% year on year to ¥79.5 billion.」

「In the Cardiovascular Company, the company proceeded with development of the next-generation product of the existing drug-eluting coronary stent Ultimaster to address more complex treatments for angina and myocardial infarction. Sales were scheduled to begin in Europe in May 2018 and in Japan in the second half of fiscal 2018.」

「Overseas, sales of access devices performed well in the TIS business of the Cardiovascular Company. At the production subsidiary in Puerto Rico, a US commonwealth, production of the Angio-Seal hemostasis device had been suspended from 20 September due to the impact of a hurricane, but resumed in November, with shipments beginning in January 2018. Sales of coils for treating cerebral aneurysms and other products also performed well and increased revenue in the Neurovascular business. The Blood Systems Company likewise posted revenue growth in sales to blood centers and in the apheresis treatment field, resulting in higher overseas revenue overall.」

「Overseas, sales of access devices, including hemostasis devices, and the drug-eluting coronary stent Ultimaster performed well in the TIS business. Sales of hydrogel-based coils for treating cerebral aneurysms and aspiration catheters also performed well in the Neurovascular business. The CV business likewise posted strong sales of oxygenators and increased revenue. As a result, overseas revenue rose substantially. Revenue at the Cardiovascular Company increased 29.6% year on year to ¥157.6 billion.」

「In the Cardiovascular Company, the company expanded the Ultimaster lineup in Japan, launching products with a 4 mm stent diameter in August 2016 and a 2.25 mm diameter in February 2017.」

「The drug-eluting coronary stent Ultimaster continued to expand its sales regions, with sales beginning in France, Brazil and South Korea during the fiscal year. In Japan, a product with a 4 mm stent diameter was added to the lineup in August, and the company focused on expanding sales.」

「In the Cardiovascular Company, sales of access devices performed well in the catheter (TIS) business. The drug-eluting coronary stent Ultimaster also began sales in France, Brazil and South Korea during the fiscal year and performed steadily in each region. In Japan, a product with a 4 mm stent diameter was added to the lineup and sales began in August.」

「The drug-eluting coronary stent Ultimaster was launched in Brazil, South Korea and Taiwan, following France.」

「The drug-eluting coronary stent Ultimaster was launched in Japan in October 2015. Sales remained strong in each region, including Europe, Central and South America, and Asia, where sales began in the previous fiscal year.」